{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:28:49Z","timestamp":1791084529010,"version":"4.1.0"},"reference-count":78,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Follicular lymphoma constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and its morphologic and biologic features. Some rare locations of extranodal involvement, such as the gastrointestinal tract or skin, were recently further refined. The description of the Follicular Lymphoma International Prognostic Index (FLIPI) represents an important step in identifying patient subgroups with predictable outcome and comparing the results of clinical trials, although its use in clinical practice remains to be established. Analyses of gene expression profiles or constitutive gene variations may also provide additional insights for prognostication in the near future. Furthermore, these data underline the complex interactions between the tumor cells and their microenvironment; recent attempts to translate these findings with immunohistochemical studies remain unable to robustly predict patient outcome. The therapeutic strategies in follicular lymphoma have been transformed by monoclonal antibodies, used alone or in combination with chemotherapy. Treatment options should be adapted to the clinical features at diagnosis and appear to be able to modify the overall survival of some subgroups of patients. Further efforts may focus on strategies that can alter the natural history of this disease.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.216","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Clinical Features, Prognosis and Treatment of Follicular Lymphoma"],"prefix":"10.1182","volume":"2007","author":[{"given":"Gilles A.","family":"Salles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704312884900_R1","doi-asserted-by":"crossref","unstructured":"Goodlad JR, MacPherson S, Jackson R, Batstone P, White J. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology. 2004;44:268\u2013276.","DOI":"10.1111\/j.1365-2559.2004.01804.x"},{"key":"2019111704312884900_R2","doi-asserted-by":"crossref","unstructured":"Damaj G, Verkarre V, Delmer A, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol. 2003;14:623\u2013629.","DOI":"10.1093\/annonc\/mdg168"},{"key":"2019111704312884900_R3","doi-asserted-by":"crossref","unstructured":"Poggi MM, Cong PJ, Coleman CN, Jaffe ES. Low-grade follicular lymphoma of the small intestine. J Clin Gastroenterol. 2002;34:155\u2013159.","DOI":"10.1097\/00004836-200202000-00011"},{"key":"2019111704312884900_R4","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u20133785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"2019111704312884900_R5","doi-asserted-by":"crossref","unstructured":"Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH. Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol. 2005;29:69\u201382.","DOI":"10.1097\/01.pas.0000146015.22624.c7"},{"key":"2019111704312884900_R6","doi-asserted-by":"crossref","unstructured":"Bacon CM, Ye H, Diss TC, et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol. 2007;31:1050\u20131058.","DOI":"10.1097\/PAS.0b013e31802ee4ab"},{"key":"2019111704312884900_R7","doi-asserted-by":"crossref","unstructured":"Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99:1959\u20131964.","DOI":"10.1182\/blood.V99.6.1959"},{"key":"2019111704312884900_R8","doi-asserted-by":"crossref","unstructured":"Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood. 2002;99:3376\u20133382.","DOI":"10.1182\/blood.V99.9.3376"},{"key":"2019111704312884900_R9","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u2013586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"2019111704312884900_R10","doi-asserted-by":"crossref","unstructured":"Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652\u2013659.","DOI":"10.1002\/cncr.22807"},{"key":"2019111704312884900_R11","doi-asserted-by":"crossref","unstructured":"Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175\u2013183.","DOI":"10.1002\/cncr.21967"},{"key":"2019111704312884900_R12","doi-asserted-by":"crossref","unstructured":"Wohrer S, Jaeger U, Kletter K, et al. 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17:780\u2013784.","DOI":"10.1093\/annonc\/mdl014"},{"key":"2019111704312884900_R13","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Musuraca G, Alinari L, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma. 2007;7:291\u2013295.","DOI":"10.3816\/CLM.2007.n.005"},{"key":"2019111704312884900_R14","doi-asserted-by":"crossref","unstructured":"Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005:314\u2013320.","DOI":"10.1182\/asheducation-2005.1.314"},{"key":"2019111704312884900_R15","doi-asserted-by":"crossref","unstructured":"Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726\u20131733.","DOI":"10.1200\/JCO.1995.13.7.1726"},{"key":"2019111704312884900_R16","doi-asserted-by":"crossref","unstructured":"Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587\u20131594.","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"2019111704312884900_R17","doi-asserted-by":"crossref","unstructured":"Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426\u20132433.","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"2019111704312884900_R18","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u20131265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"2019111704312884900_R19","doi-asserted-by":"crossref","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986\u20131992.","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"2019111704312884900_R20","doi-asserted-by":"crossref","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504\u20131508.","DOI":"10.1182\/blood-2006-01-013367"},{"key":"2019111704312884900_R21","doi-asserted-by":"crossref","unstructured":"Marcus R, Solal-Celigny P, Imrie K, al. e. Rituximab plus CVP improves survival in previously untreated patients with advanced follicular non-Hodgkin\u2019s lymphoma [abstract]. Blood. 2006;108:481a.","DOI":"10.1182\/blood.V108.11.481.481"},{"key":"2019111704312884900_R22","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Salles G, Brousse N, al. E. Single four-dose rituximab treatment for low-tumour burden follicular lymphoma: survival analyses with a follow-up of at least 5 years [abstract]. Blood. 2004;104:169a.","DOI":"10.1182\/blood.V104.11.585.585"},{"key":"2019111704312884900_R23","doi-asserted-by":"crossref","unstructured":"Gascoyne R. Follicular lymphoma: pathology and biology. Hematology. 2004:203\u2013208.","DOI":"10.1182\/asheducation-2004.1.203"},{"key":"2019111704312884900_R24","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363\u20132367.","DOI":"10.1182\/blood-2002-07-2298"},{"key":"2019111704312884900_R25","doi-asserted-by":"crossref","unstructured":"Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol. 2006;17:920\u2013927.","DOI":"10.1093\/annonc\/mdl039"},{"key":"2019111704312884900_R26","doi-asserted-by":"crossref","unstructured":"Tilly H, Rossi A, Stamatoullas A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 1994;84:1043\u20131049.","DOI":"10.1182\/blood.V84.4.1043.1043"},{"key":"2019111704312884900_R27","doi-asserted-by":"crossref","unstructured":"Hoglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39:195\u2013204.","DOI":"10.1002\/gcc.10314"},{"key":"2019111704312884900_R28","doi-asserted-by":"crossref","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159\u20132169.","DOI":"10.1056\/NEJMoa041869"},{"key":"2019111704312884900_R29","doi-asserted-by":"crossref","unstructured":"Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25:390\u2013398.","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"2019111704312884900_R30","doi-asserted-by":"crossref","unstructured":"Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169\u20132174.","DOI":"10.1182\/blood-2005-04-1565"},{"key":"2019111704312884900_R31","doi-asserted-by":"crossref","unstructured":"Canioni D, Salles G, Mounier N, et al. The poor prognosis value of high tumoral macrophage counts in follicular lymphoma patients requires selection of appropriate cut-off and can be circumvented by Rituximab therapy [abstract]. Blood. 2006;108: abstract no. 822.","DOI":"10.1182\/blood.V108.11.822.822"},{"key":"2019111704312884900_R32","unstructured":"Alvaro T, Lejeune M, Camacho FL, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91:1605\u20131612."},{"key":"2019111704312884900_R33","doi-asserted-by":"crossref","unstructured":"Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350\u20135357.","DOI":"10.1200\/JCO.2006.06.4766"},{"key":"2019111704312884900_R34","doi-asserted-by":"crossref","unstructured":"Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13:388\u2013397.","DOI":"10.1158\/1078-0432.CCR-06-1734"},{"key":"2019111704312884900_R35","doi-asserted-by":"crossref","unstructured":"Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957\u20132964.","DOI":"10.1182\/blood-2006-04-018218"},{"key":"2019111704312884900_R36","doi-asserted-by":"crossref","unstructured":"Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052\u20135059.","DOI":"10.1200\/JCO.2006.06.4642"},{"key":"2019111704312884900_R37","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma. Cancer Res. 2006;66:10145\u201310152.","DOI":"10.1158\/0008-5472.CAN-06-1822"},{"key":"2019111704312884900_R38","doi-asserted-by":"crossref","unstructured":"Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u2013949.","DOI":"10.1038\/nm1093"},{"key":"2019111704312884900_R39","doi-asserted-by":"crossref","unstructured":"Ai WYZ, Czerwinski D, Horning SJ, Allen J, Tibshirani R, Levy R. Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma [abstract]. Blood. 2006;108;824a.","DOI":"10.1182\/blood.V108.11.824.824"},{"key":"2019111704312884900_R40","doi-asserted-by":"crossref","unstructured":"de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2014a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25:805\u2013812.","DOI":"10.1200\/JCO.2006.09.4490"},{"key":"2019111704312884900_R41","doi-asserted-by":"crossref","unstructured":"Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007;109:5439\u20135446.","DOI":"10.1182\/blood-2006-11-058040"},{"key":"2019111704312884900_R42","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol. 1993;20:75\u201388."},{"key":"2019111704312884900_R43","doi-asserted-by":"crossref","unstructured":"Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582\u20131589.","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"2019111704312884900_R44","doi-asserted-by":"crossref","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447\u20138452.","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"2019111704312884900_R45","doi-asserted-by":"crossref","unstructured":"Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007;109:2077\u20132082.","DOI":"10.1002\/cncr.22649"},{"key":"2019111704312884900_R46","doi-asserted-by":"crossref","unstructured":"Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019\u20135026.","DOI":"10.1200\/JCO.2005.04.503"},{"key":"2019111704312884900_R47","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood. 2005;106:106a.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"2019111704312884900_R48","doi-asserted-by":"crossref","unstructured":"Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215\u20132223.","DOI":"10.1200\/JCO.2005.06.146"},{"key":"2019111704312884900_R49","doi-asserted-by":"crossref","unstructured":"Lister TA. Improved survival for patients with follicular lymphoma. J Clin Oncol. 2005;23:4830\u20134831.","DOI":"10.1200\/JCO.2005.03.911"},{"key":"2019111704312884900_R50","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052\u20133056.","DOI":"10.1182\/blood.V95.10.3052"},{"key":"2019111704312884900_R51","doi-asserted-by":"crossref","unstructured":"Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101\u2013106.","DOI":"10.1182\/blood.V97.1.101"},{"key":"2019111704312884900_R52","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416\u20134423.","DOI":"10.1182\/blood-2003-10-3411"},{"key":"2019111704312884900_R53","doi-asserted-by":"crossref","unstructured":"Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103\u20131108.","DOI":"10.1200\/JCO.2005.12.052"},{"key":"2019111704312884900_R54","doi-asserted-by":"crossref","unstructured":"Colombat P, Salles G, Brousse N, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 year [abstract]. Blood. 2006;108: abstract no. 486.","DOI":"10.1182\/blood.V108.11.486.486"},{"key":"2019111704312884900_R55","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:4261\u20134267.","DOI":"10.1200\/JCO.2002.08.674"},{"key":"2019111704312884900_R56","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088\u20131095.","DOI":"10.1200\/JCO.2005.12.191"},{"key":"2019111704312884900_R57","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Meng C, Spigel DR, al. E. Long-term followup of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab: response to rituximab retreatment at progression [abstract]. Blood. 2006;108: abstract no. 4723.","DOI":"10.1182\/blood.V108.11.4723.4723"},{"key":"2019111704312884900_R58","doi-asserted-by":"crossref","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u20131423.","DOI":"10.1182\/blood-2004-08-3175"},{"key":"2019111704312884900_R59","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u20133732.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"2019111704312884900_R60","doi-asserted-by":"crossref","unstructured":"Salles G, Foussard C, Mounier N, et al. Rituximab added to \u03b1IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood. 2004;104:160a.","DOI":"10.1182\/blood.V104.11.160.160"},{"key":"2019111704312884900_R61","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856\u2013862.","DOI":"10.1182\/blood.V99.3.856"},{"key":"2019111704312884900_R62","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol. 2004;22:2654\u20132661.","DOI":"10.1200\/JCO.2004.07.170"},{"key":"2019111704312884900_R63","doi-asserted-by":"crossref","unstructured":"Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706\u2013714.","DOI":"10.1093\/jnci\/djk152"},{"key":"2019111704312884900_R64","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441\u2013449.","DOI":"10.1056\/NEJMoa041511"},{"key":"2019111704312884900_R65","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143\u20134149.","DOI":"10.1200\/JCO.2006.05.8198"},{"key":"2019111704312884900_R66","doi-asserted-by":"crossref","unstructured":"Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696\u20135704.","DOI":"10.1200\/JCO.2005.14.803"},{"key":"2019111704312884900_R67","doi-asserted-by":"crossref","unstructured":"Shipley DL, Greco FA, Spigel DR. Rituximab with short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial [abstract]. Proc ASCO. 2005;23:579s.","DOI":"10.1200\/jco.2005.23.16_suppl.6577"},{"key":"2019111704312884900_R68","doi-asserted-by":"crossref","unstructured":"Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin\u2019s lymphomas. Hematol Oncol. 2005;23:10\u201317.","DOI":"10.1002\/hon.743"},{"key":"2019111704312884900_R69","doi-asserted-by":"crossref","unstructured":"Plancarte F, Lopez-Guillermo A, Arenillas L, et al. Follicular lymphoma in early stages: high-risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol. 2006;76:58\u201363.","DOI":"10.1111\/j.1600-0609.2005.00564.x"},{"key":"2019111704312884900_R70","doi-asserted-by":"crossref","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454\u20131459.","DOI":"10.1200\/JCO.2004.10.086"},{"key":"2019111704312884900_R71","doi-asserted-by":"crossref","unstructured":"Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I\u2013II indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:2115\u20132122.","DOI":"10.1200\/JCO.2003.07.111"},{"key":"2019111704312884900_R72","doi-asserted-by":"crossref","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20131117.","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"2019111704312884900_R73","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003:516\u2013522.","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"2019111704312884900_R74","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Morrissey LH, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin\u2019s lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol. 2005;23:1500\u20131506.","DOI":"10.1200\/JCO.2005.05.004"},{"key":"2019111704312884900_R75","doi-asserted-by":"crossref","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295\u20133301.","DOI":"10.1182\/blood-2006-05-021113"},{"key":"2019111704312884900_R76","doi-asserted-by":"crossref","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003\u20134008.","DOI":"10.1182\/blood-2006-04-016725"},{"key":"2019111704312884900_R77","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705\u2013711.","DOI":"10.1200\/JCO.2005.04.164"},{"key":"2019111704312884900_R78","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711\u20134716.","DOI":"10.1200\/JCO.2004.04.020"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/216\/646237\/216_225ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/216\/646237\/216_225ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T06:58:06Z","timestamp":1588057086000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/216\/19184\/Clinical-Features-Prognosis-and-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.216","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}